<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2023-5259</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-5259</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МНЕНИЕ ПО ПРОБЛЕМЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPINION ON THE ISSUE</subject></subj-group></article-categories><title-group><article-title>«Красные флаги» диагностики инфильтративных заболеваний сердца</article-title><trans-title-group xml:lang="en"><trans-title>Red flags to diagnose infiltrative cardiomyopathies</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7479-418X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Резник</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Reznik</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Резник Елена Владимировна — доктор медицинских наук, доцент, заведующий кафедрой пропедевтики внутренних болезней лечебного факультета, врач-кардиолог, терапевт, врач функциональной диагностики</p><p>119415, г. Москва, ул. Лобачевского д. 42</p></bio><bio xml:lang="en"><p>Elena V. Reznik, MD, assistant professor, Head of the Department of Propedeutics of Internal Diseases of the medical faculty of the Pirogov Russian national research medical University of the Ministry of healthcare of the Russian Federation, Moscow; Cardiologist of the GBUZ "City Clinical Hospital №31" of Healthcare Department </p><p>Moscow, Lobachevsky street, 42</p></bio><email xlink:type="simple">elenaresnik@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8856-4542</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нгуен</surname><given-names>Т. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nguyen</surname><given-names>T. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нгуен Тхань Луан — аспирант кафедры пропедевтики внутренних болезней лечебного факультета</p><p>Москва, Островитянова, д.1</p></bio><bio xml:lang="en"><p>Thanh Luan Nguyen, Ph.D student, Department of Propedeutics of Internal Diseases of the medical faculty </p><p>Moscow, Ostrovityanova Street 1</p></bio><email xlink:type="simple">truongthianh0302@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0402-3977</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Устюжанин</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ustyuzhanin</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Устюжанин Дмитрий Владимирович — кандидат медицинских наук, старший научный сотрудник отдела томографии</p><p>121552, г. Москва, ул. 3-я Черепковская 15 а</p></bio><bio xml:lang="en"><p>Dmitry V. Ustyuzhanin, PhD, Researcher at tomography department</p><p>121552, Moscow, 3rd Cherepkovskaya Str. 15a</p><p> </p><p> </p><p> </p></bio><email xlink:type="simple">d-ust@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4026-3791</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семячкина</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Semyachkina</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Семячкина Алла Николаевна — доктор медицинских наук, профессор, главный научный сотрудник отдела клинической генетики Научно-исследовательского клинического института педиатрии имени акад. Ю. Е. Вельтищева</p><p>125412, Москва, ул. Талдомская, д.2</p></bio><bio xml:lang="en"><p>Alla A. Semyachkina, MD, professor, Chief Researcher of the Department of Clinical Genetics, Veltischev Research and Clinical Institute for Pediatrics </p><p>125412, Moscow, st. Taldomskaya, 2</p><p> </p><p> </p></bio><email xlink:type="simple">asemyachkina@pedklin.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7115-0186</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Школьникова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shkolnikova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Школьникова Мария Александровна — доктор медицинских наук, профессор, научный руководитель, заведующий детским научно-практическим центром нарушений сердечного ритма, врач-детский кардиолог Научно-исследовательского клинического института педиатрии им. акад. Ю. Е. Вельтищева</p><p>125412, Москва, ул. Талдомская, д.2</p></bio><bio xml:lang="en"><p>Maria A. Shkolnikova , MD, Professor, Scientific Supervisor, Head of the Children's Scientific and Practical Center for Heart Rhythm Disorders of the Ministry of Health of the Russian Federation, Pediatric Cardiologist, Veltischev Research and Clinical Institute for Pediatrics </p><p>125412, Moscow, st. Taldomskaya, 2</p></bio><email xlink:type="simple">niki@pedklin.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава России;&#13;
ГБУЗ ГКБ № 31 ДЗМ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University; &#13;
City Clinical Hospital №31</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава России</institution><country>Вьетнам</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution><country>Viet Nam</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ Национальный медицинский исследовательский центр кардиологии им. акад. Е. И. Чазова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E. I. Chazov National Medical Research Center of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>25</day><month>01</month><year>2023</year></pub-date><volume>28</volume><issue>1S</issue><issue-title>Образование</issue-title><fpage>5259</fpage><lpage>5259</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Резник Е.В., Нгуен Т.Л., Устюжанин Д.В., Семячкина А.Н., Школьникова М.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Резник Е.В., Нгуен Т.Л., Устюжанин Д.В., Семячкина А.Н., Школьникова М.А.</copyright-holder><copyright-holder xml:lang="en">Reznik E.V., Nguyen T.L., Ustyuzhanin D.V., Semyachkina A.N., Shkolnikova M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/5259">https://russjcardiol.elpub.ru/jour/article/view/5259</self-uri><abstract><p>Инфильтративные заболевания сердца — группа заболеваний, характеризующаяся отложением аномальных веществ в ткани сердца, что приводит к утолщению стенок или расширению камер сердца с вторичным уменьшением толщины стенки и развитию диастолической, реже — систолической, дисфункции желудочка(ов). Чаще всего это прогрессирующие заболевания, которые при отсутствии адекватной терапии имеют неблагоприятный прогноз. Клинические проявления инфильтративных заболеваний сердца вариабельны, что часто приводит к диагностическим затруднениям и ошибкам. Для подтверждения или уточнения диагноза в большинстве случаев необходимы специфические лабораторные и морфологические исследования. Своевременная диагностика имеет решающее значение для начала терапии и улучшения прогноза пациентов. В данной статье предоставлены характерные признаки и симптомы, так называемые "красные флаги" или "ключи диагностики", позволяющие заподозрить инфильтративные заболевания сердца, диагностировать их на ранних этапах и начать жизнеспасающую терапию.</p></abstract><trans-abstract xml:lang="en"><p>Infiltrative cardiomyopathies are a group of diseases characterized by the deposition of abnormal substances in heart tissues, which leads to thickening of the walls or dilation of chambers with a secondary decrease in wall thickness and the development of diastolic, less often systolic, ventricular dysfunction. Most often, these are progressive diseases that, in the absence of adequate therapy, have an unfavorable prognosis. Clinical manifestations of infiltrative cardiac diseases are variable, which often leads to diagnostic difficulties and errors. In most cases, specific laboratory and morphological tests are required to confirm or clarify the diagnosis. Early diagnosis is critical to initiating therapy and improving patient prognosis. This article provides characteristic signs and symptoms, the so-called "red flags", making it possible to suspect infiltrative cardiomyopathies, diagnose them at an early stage and start life-saving therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инфильтративные заболевания сердца</kwd><kwd>инфильтративные кардиомиопатии</kwd><kwd>красные флаги</kwd><kwd>ключи диагностики</kwd><kwd>амилоидоз</kwd><kwd>саркоидоз</kwd><kwd>гемохроматоз</kwd><kwd>болезнь Фабри</kwd><kwd>мукополисахаридоз</kwd><kwd>болезнь Данона</kwd><kwd>болезнь Помпе</kwd><kwd>сердечная недостаточность</kwd><kwd>аритмия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>infiltrative heart diseases</kwd><kwd>infiltrative cardiomyopathies</kwd><kwd>red flags</kwd><kwd>diagnostic keys</kwd><kwd>amyloidosis</kwd><kwd>sarcoidosis</kwd><kwd>hemochromatosis</kwd><kwd>Fabry disease</kwd><kwd>mucopolysaccharidosis</kwd><kwd>Danon disease</kwd><kwd>Pompe disease</kwd><kwd>heart failure</kwd><kwd>arrhythmia</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kushwaha SS, Fallon JT, Fuster V. Restrictive Cardiomyopathy. New England Journal of Medicine. 1997;336:267-76. doi:10.1056/NEJM199701233360407.</mixed-citation><mixed-citation xml:lang="en">Kushwaha SS, Fallon JT, Fuster V. Restrictive Cardiomyopathy. New England Journal of Medicine. 1997;336:267-76. doi:10.1056/NEJM199701233360407.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Seward J, Verzosa G. Infiltrative Cardiovascular Diseases. Cardiomyopathies That Look Alike. Journal of the American College of Cardiology. 2010;55:1769-79. doi:10.1016/j.jacc.2009.12.040.</mixed-citation><mixed-citation xml:lang="en">Seward J, Verzosa G. Infiltrative Cardiovascular Diseases. Cardiomyopathies That Look Alike. Journal of the American College of Cardiology. 2010;55:1769-79. doi:10.1016/j.jacc.2009.12.040.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Madan N, Kalra D. Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020;21:181-90. doi:10.31083/j.rcm.2020.02.65.</mixed-citation><mixed-citation xml:lang="en">Madan N, Kalra D. Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020;21:181-90. doi:10.31083/j.rcm.2020.02.65.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Braunwald E, Zipes DP, Libby P. Heart Disease: A Textbook of Cardiovascular Medicine. Saunders 2001. 2297 p. ISBN: 0721685617.</mixed-citation><mixed-citation xml:lang="en">Braunwald E, Zipes DP, Libby P. Heart Disease: A Textbook of Cardiovascular Medicine. Saunders 2001. 2297 p. ISBN: 0721685617.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев В.С. Кардиомиопатии и миокардиты. ГЭОТАР-Медиа, 2020. 512 с. ISBN: 978-5-9704-5429-9.</mixed-citation><mixed-citation xml:lang="en">Moiseev VS. Cardiomyopathy and myocarditis. GEOTAR-Media, 2020. 512 p. (In Russ.) ISBN: 978-5-9704-5429-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. European Journal of Preventive Cardiology. 2020;27:1806-15. doi:10.1177/2047487319877708.</mixed-citation><mixed-citation xml:lang="en">Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. European Journal of Preventive Cardiology. 2020;27:1806-15. doi:10.1177/2047487319877708.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев А.С., Моисеев С.В., Тао Е.А. и др. Клинические проявления и исходы болезни Фабри у 150 взрослых пациентов. Клиническая фармакология и терапия. 2021;30:43-51. doi:10.32756/0869-5490-2021-3-43-51.</mixed-citation><mixed-citation xml:lang="en">Moiseev AS, Moiseev SV, Tao EA, et al. Clinical manifestations and outcomes of Fabry disease in 150 adult patients. Clinical pharmacology and therapy. 2021;30:43-51. (In Russ.) doi:10.32756/0869-5490-2021-3-43-51.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Weidemann F, Reiser M. Fabry Disease. JACC: Cardiovascular Imaging. 2019;12:1684-5. doi:10.1016/j.jcmg.2018.05.029.</mixed-citation><mixed-citation xml:lang="en">Weidemann F, Reiser M. Fabry Disease. JACC: Cardiovascular Imaging. 2019;12:1684-5. doi:10.1016/j.jcmg.2018.05.029.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K, et al. Diagnosis of Mucopolysaccharidoses. Diagnostics (Basel). 2020;10:172. doi:10.3390/diagnostics10030172.</mixed-citation><mixed-citation xml:lang="en">Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K, et al. Diagnosis of Mucopolysaccharidoses. Diagnostics (Basel). 2020;10:172. doi:10.3390/diagnostics10030172.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cenacchi G, Papa V, Pegoraro V, et al. Review: Danon disease: Review of natural history and recent advances. Neuropathol Appl Neurobiol. 2020;46:303-22. doi:10.1111/nan.12587.</mixed-citation><mixed-citation xml:lang="en">Cenacchi G, Papa V, Pegoraro V, et al. Review: Danon disease: Review of natural history and recent advances. Neuropathol Appl Neurobiol. 2020;46:303-22. doi:10.1111/nan.12587.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cook A, Giunti P. Friedreich’s ataxia: clinical features, pathogenesis and management. British Medical Bulletin. 2017;124:19-30. doi:10.1093/bmb/ldx034.</mixed-citation><mixed-citation xml:lang="en">Cook A, Giunti P. Friedreich’s ataxia: clinical features, pathogenesis and management. British Medical Bulletin. 2017;124:19-30. doi:10.1093/bmb/ldx034.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Díez-López C, Comín-Colet J, González-Costello J. Iron overload cardiomyopathy: from diagnosis to management. Current Opinion in Cardiology. 2018;33:334-40. doi:10.1097/HCO.0000000000000511.</mixed-citation><mixed-citation xml:lang="en">Díez-López C, Comín-Colet J, González-Costello J. Iron overload cardiomyopathy: from diagnosis to management. Current Opinion in Cardiology. 2018;33:334-40. doi:10.1097/HCO.0000000000000511.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Резник Е.В., Нгуен Т.Л., Степанова Е.А. и др. Амилоидоз сердца: взгляд терапевта и кардиолога. Архивъ внутренней медицины. 2020;10:430-57. doi:10.20514/2226-6704-2020-10-6-430-457.</mixed-citation><mixed-citation xml:lang="en">Reznik EV, Nguyen TL, Stepanova EA, et al. Amyloidosis of the heart: the view of the therapist and cardiologist. Archives of Internal Medicine. 2020;10:430-57. (In Russ.) doi:10.20514/2226-6704-2020-10-6-430-457.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Резник Е.В., Степанова E.A., Нгуен Т.Л. и др. Ретроспективный анализ поражения сердечно-сосудистой системы у больных системным амилоидозом. Кардиоваскулярная терапия и профилактика. 2021;20(1):2496. doi:10.15829/1728-8800-2021-2496.</mixed-citation><mixed-citation xml:lang="en">Reznik EV, Stepanova EA, Nguyen TL, et al. Retrospective analysis of damage to the cardiovascular system in patients with systemic amyloidosis. Cardiovascular Therapy and Prevention. 2021;20(1):2496. (In Russ.) doi:10.15829/1728-8800-2021-2496.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Singh MM, Kumar R, Tewari S, et al. Determining Nt-proBNP Levels with Diastolic Dysfunction in Thalassemia Major Patients. J Pediatr Genet. 2017;6:222-6. doi:10.1055/s-0037-1603193.</mixed-citation><mixed-citation xml:lang="en">Singh MM, Kumar R, Tewari S, et al. Determining Nt-proBNP Levels with Diastolic Dysfunction in Thalassemia Major Patients. J Pediatr Genet. 2017;6:222-6. doi:10.1055/s-0037-1603193.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Child JS, Perloff JK, Bach PM, et al. Cardiac involvement in Friedreich’s ataxia: A clinical study of 75 patients. Journal of the American College of Cardiology. 1986;7:1370-8. doi:10.1016/S0735-1097(86)80159-0.</mixed-citation><mixed-citation xml:lang="en">Child JS, Perloff JK, Bach PM, et al. Cardiac involvement in Friedreich’s ataxia: A clinical study of 75 patients. Journal of the American College of Cardiology. 1986;7:1370-8. doi:10.1016/S0735-1097(86)80159-0.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Namdar M, Steffel J, Jetzer S, et al. Value of Electrocardiogram in the Differentiation of Hypertensive Heart Disease, Hypertrophic Cardiomyopathy, Aortic Stenosis, Amyloidosis, and Fabry Disease. The American Journal of Cardiology. 2012;109:587-93. doi:10.1016/j.amjcard.2011.09.052.</mixed-citation><mixed-citation xml:lang="en">Namdar M, Steffel J, Jetzer S, et al. Value of Electrocardiogram in the Differentiation of Hypertensive Heart Disease, Hypertrophic Cardiomyopathy, Aortic Stenosis, Amyloidosis, and Fabry Disease. The American Journal of Cardiology. 2012;109:587-93. doi:10.1016/j.amjcard.2011.09.052.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Serra W, Marziliano N. Role of cardiac imaging in Anderson-Fabry cardiomyopathy. Cardiovasc Ultrasound 2019;17:1. doi:10.1186/s12947-019-0151-5.</mixed-citation><mixed-citation xml:lang="en">Serra W, Marziliano N. Role of cardiac imaging in Anderson-Fabry cardiomyopathy. Cardiovasc Ultrasound 2019;17:1. doi:10.1186/s12947-019-0151-5.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Fatehi F, Ashrafi MR, Babaee M, et al. Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus. Frontiers in Neurology. 2021;12. doi:10.3389/fneur.2021.739931.</mixed-citation><mixed-citation xml:lang="en">Fatehi F, Ashrafi MR, Babaee M, et al. Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus. Frontiers in Neurology. 2021;12. doi:10.3389/fneur.2021.739931.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Albakri A. Deposition diseases cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management. Trends in Research. 2019;2. doi:10.15761/TR.1000147.</mixed-citation><mixed-citation xml:lang="en">Albakri A. Deposition diseases cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management. Trends in Research. 2019;2. doi:10.15761/TR.1000147.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenfeld LE, Chung MK, Harding CV, et al. Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation: Arrhythmia and Electrophysiology. 2021;14:e009203. doi:10.1161/CIRCEP.120.009203.</mixed-citation><mixed-citation xml:lang="en">Rosenfeld LE, Chung MK, Harding CV, et al. Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation: Arrhythmia and Electrophysiology. 2021;14:e009203. doi:10.1161/CIRCEP.120.009203.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yamada S, Yoshihisa A, Hijioka N, et al. Autonomic dysfunction in cardiac amyloidosis assessed by heart rate variability and heart rate turbulence. Ann Noninvasive Electrocardiol. 2020;25:e12749. doi:10.1111/anec.12749.</mixed-citation><mixed-citation xml:lang="en">Yamada S, Yoshihisa A, Hijioka N, et al. Autonomic dysfunction in cardiac amyloidosis assessed by heart rate variability and heart rate turbulence. Ann Noninvasive Electrocardiol. 2020;25:e12749. doi:10.1111/anec.12749.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Azevedo O, Marques N, Reis L, et al. Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy? American Heart Journal. 2020;226:114-26. doi:10.1016/j.ahj.2020.04.006.</mixed-citation><mixed-citation xml:lang="en">Azevedo O, Marques N, Reis L, et al. Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy? American Heart Journal. 2020;226:114-26. doi:10.1016/j.ahj.2020.04.006.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki T, Kanda T, Kubota S, et al. Holter Monitoring as a Noninvasive Indicator of Cardiac Involvement in Sarcoidosis. CHEST. 1994;106:1021-4. doi:10.1378/chest.106.4.1021.</mixed-citation><mixed-citation xml:lang="en">Suzuki T, Kanda T, Kubota S, et al. Holter Monitoring as a Noninvasive Indicator of Cardiac Involvement in Sarcoidosis. CHEST. 1994;106:1021-4. doi:10.1378/chest.106.4.1021.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hu K, Liu D, Salinger T, et al. Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function. J Thorac Dis. 2018;10:4966-75. doi:10.21037/jtd.2018.07.56.</mixed-citation><mixed-citation xml:lang="en">Hu K, Liu D, Salinger T, et al. Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function. J Thorac Dis. 2018;10:4966-75. doi:10.21037/jtd.2018.07.56.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Perfetto F, Zampieri M, Fumagalli C, et al. Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Intern Emerg Med. 2022;17:957- 69. doi:10.1007/s11739-022-02958-2.</mixed-citation><mixed-citation xml:lang="en">Perfetto F, Zampieri M, Fumagalli C, et al. Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Intern Emerg Med. 2022;17:957- 69. doi:10.1007/s11739-022-02958-2.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Seydelmann N, Liu D, Krämer J, et al. High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease. Journal of the American Heart Association. 2016;5:e002839. doi:10.1161/JAHA.115.002839.</mixed-citation><mixed-citation xml:lang="en">Seydelmann N, Liu D, Krämer J, et al. High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease. Journal of the American Heart Association. 2016;5:e002839. doi:10.1161/JAHA.115.002839.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Baba Y, Kubo T, Kawaguchi J, et al. High sensitivity cardiac troponin T is a useful biomarker for predicting prognosis of the patients with sarcoidosis. European Heart Journal. 2020;41:ehaa946.2121. doi:10.1093/ehjci/ehaa946.2121.</mixed-citation><mixed-citation xml:lang="en">Baba Y, Kubo T, Kawaguchi J, et al. High sensitivity cardiac troponin T is a useful biomarker for predicting prognosis of the patients with sarcoidosis. European Heart Journal. 2020;41:ehaa946.2121. doi:10.1093/ehjci/ehaa946.2121.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Takashio S, Yamamuro M, Izumiya Y, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2017;5:27-35. doi:10.1002/ehf2.12203.</mixed-citation><mixed-citation xml:lang="en">Takashio S, Yamamuro M, Izumiya Y, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2017;5:27-35. doi:10.1002/ehf2.12203.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. European Heart Journal. 2018;39:2799-806. doi:10.1093/eurheartj/ehx589.</mixed-citation><mixed-citation xml:lang="en">Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. European Heart Journal. 2018;39:2799-806. doi:10.1093/eurheartj/ehx589.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Arvanitis M, Simon S, Chan G, et al. Utility of Retinol Binding Protein 4 (RBP4) concentration for screening of V122I transthyretin cardiac amyloidosis. Amyloid. 2017;24:120-1. doi:10.1080/13506129.2017.1295371.</mixed-citation><mixed-citation xml:lang="en">Arvanitis M, Simon S, Chan G, et al. Utility of Retinol Binding Protein 4 (RBP4) concentration for screening of V122I transthyretin cardiac amyloidosis. Amyloid. 2017;24:120-1. doi:10.1080/13506129.2017.1295371.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Heaney JLJ, Richter A, Bowcock S, et al. Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels. Haematologica. 2020;105:e169-71. doi:10.3324/haematol.2019.224360.</mixed-citation><mixed-citation xml:lang="en">Heaney JLJ, Richter A, Bowcock S, et al. Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels. Haematologica. 2020;105:e169-71. doi:10.3324/haematol.2019.224360.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. NEJM. 2005;352. doi:10.1056/NEJMoa033349.</mixed-citation><mixed-citation xml:lang="en">Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. NEJM. 2005;352. doi:10.1056/NEJMoa033349.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Demoulin N, Aydin S, Gillion V, et al. Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review. American Journal of Kidney Diseases. 2022;79:717- 27. doi:10.1053/j.ajkd.2021.07.018.</mixed-citation><mixed-citation xml:lang="en">Demoulin N, Aydin S, Gillion V, et al. Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review. American Journal of Kidney Diseases. 2022;79:717- 27. doi:10.1053/j.ajkd.2021.07.018.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Azevedo O, Cordeiro F, Gago MF, et al. Fabry Disease and the Heart: A Comprehensive Review. International Journal of Molecular Sciences. 2021;22:4434. doi:10.3390/ijms22094434.</mixed-citation><mixed-citation xml:lang="en">Azevedo O, Cordeiro F, Gago MF, et al. Fabry Disease and the Heart: A Comprehensive Review. International Journal of Molecular Sciences. 2021;22:4434. doi:10.3390/ijms22094434.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Houston BA, Mukherjee M. Cardiac sarcoidosis: clinical manifestations, imaging characteristics, and therapeutic approach. Clin Med Insights Cardiol. 2014;8:31-7. doi:10.4137/CMC.S15713.</mixed-citation><mixed-citation xml:lang="en">Houston BA, Mukherjee M. Cardiac sarcoidosis: clinical manifestations, imaging characteristics, and therapeutic approach. Clin Med Insights Cardiol. 2014;8:31-7. doi:10.4137/CMC.S15713.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Гуринова Е.Е., Сухомясова А.Л., Семячкина А.Н. и др. Лечение препаратом Вимизайм (Vimizim) подростка с синдромом Моркио А (мукополисахаридозом IV A). Российский вестник перинатологии и педиатрии. 2021;66(4):109-17. doi:10.21508/1027-4065-2021-66-4-109-117.</mixed-citation><mixed-citation xml:lang="en">Gurinova EE, Sukhomyasova AL, Semyachkina AN, et al. Treating a teenager with Morquio A syndrome (mucopolysaccharidosis IV A) with Vimizim. Russian Bulletin of Perinatology and Pediatrics. 2021;66(4):109-17. (In Russ.) doi:10.21508/1027-4065-2021-66-4-109-117.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Pagourelias ED, Duchenne J, Mirea O, et al. The Relation of Ejection Fraction and Global Longitudinal Strain in Amyloidosis: Implications for Differential Diagnosis. JACC: Cardiovascular Imaging. 2016;9:1358-9. doi:10.1016/j.jcmg.2015.11.013.</mixed-citation><mixed-citation xml:lang="en">Pagourelias ED, Duchenne J, Mirea O, et al. The Relation of Ejection Fraction and Global Longitudinal Strain in Amyloidosis: Implications for Differential Diagnosis. JACC: Cardiovascular Imaging. 2016;9:1358-9. doi:10.1016/j.jcmg.2015.11.013.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Рамеева А.С., Рамеев В.В., Бобкова И.Н. и др. Ведущие факторы прогрессирования амилоидоза сердца. Рациональная Фармакотерапия в Кардиологии. 2022;18(2):143- 52. doi:10.20996/1819-6446-2022-04-02.</mixed-citation><mixed-citation xml:lang="en">Rameeva AS, Rameev VV, Bobkova IN, et al. Leading factors in the progression of cardiac amyloidosis. Rational Pharmacotherapy in Cardiology. 2022;18(2):143-52. (In Russ.) doi:10.20996/1819-6446-2022-04-02.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Değirmenci H, Demirelli S, Arısoy A, et al. Myocardial deformation and total atrial conduction time in the prediction of cardiac involvement in patients with pulmonary sarcoidosis. Clin Respir J. 2017;11:68-77. doi:10.1111/crj.12307.</mixed-citation><mixed-citation xml:lang="en">Değirmenci H, Demirelli S, Arısoy A, et al. Myocardial deformation and total atrial conduction time in the prediction of cardiac involvement in patients with pulmonary sarcoidosis. Clin Respir J. 2017;11:68-77. doi:10.1111/crj.12307.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Титова А.М., Труфанов Г.Е., Фокин В.А. Т2* Магнит - но-резонансная релаксометрия в количественной неинвазивной оценке перегрузки железом печени и сердца. Трансляционная медицина. 2017;4:37-45. doi:10.18705/2311-4495-2017-4-5-37-45.</mixed-citation><mixed-citation xml:lang="en">Titova AM, Trufanov GE, Fokin VA. T2* Magnetic resonance relaxometry in the quantitative non-invasive evaluation of iron overload in the liver and heart. Translational Medicine 2017;4:37-45. (In Russ.) doi:10.18705/2311-4495-2017-4-5-37-45.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Попонина Ю.С., Попонина Т.М., Мочула О.В. и др. Саркоидоз сердца: трудности и возможности дифференциальной диагностики с острым коронарным синдромом без подъема сегмента ST в реальной клинической практике (клинический случай). Сибирский журнал клинической и экспериментальной медицины. 2022;37(1):142-8. doi:10.29001/2073-8552-2022-37-1-142-148.</mixed-citation><mixed-citation xml:lang="en">Poponina YuS, Poponina TM, Mochula OV, et al. Cardiac sarcoidosis: Difficulties and possibilities of differential diagnosis for acute coronary syndrome without ST segment elevation in real clinical practice. The Siberian Journal of Clinical and Experimental Medicine. 2022;37(1):142-8. (In Russ.) doi:10.29001/2073-8552-2022-37-1-142-148.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Fang T, Wang J, Kang Y, et al. The Value of Cardiac Magnetic Resonance Imaging in Identification of Rare Diseases Mimicking Hypertrophic Cardiomyopathy. Journal of Clinical Medicine. 2021;10:3339. doi:10.3390/jcm10153339.</mixed-citation><mixed-citation xml:lang="en">Fang T, Wang J, Kang Y, et al. The Value of Cardiac Magnetic Resonance Imaging in Identification of Rare Diseases Mimicking Hypertrophic Cardiomyopathy. Journal of Clinical Medicine. 2021;10:3339. doi:10.3390/jcm10153339.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Mongeon F-P, Jerosch-Herold M, Coelho-Filho OR, et al. Quantification of Extracellular Matrix Expansion by CMR in Infiltrative Heart Disease. JACC: Cardiovascular Imaging 2012;5:897-907. doi:10.1016/j.jcmg.2012.04.006.</mixed-citation><mixed-citation xml:lang="en">Mongeon F-P, Jerosch-Herold M, Coelho-Filho OR, et al. Quantification of Extracellular Matrix Expansion by CMR in Infiltrative Heart Disease. JACC: Cardiovascular Imaging 2012;5:897-907. doi:10.1016/j.jcmg.2012.04.006.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Karur GR, Robison S, Iwanochko RM, et al. Use of Myocardial T1 Mapping at 3.0 T to Differentiate Anderson-Fabry Disease from Hypertrophic Cardiomyopathy. Radiology. 2018;288:398-406. doi:10.1148/radiol.2018172613.</mixed-citation><mixed-citation xml:lang="en">Karur GR, Robison S, Iwanochko RM, et al. Use of Myocardial T1 Mapping at 3.0 T to Differentiate Anderson-Fabry Disease from Hypertrophic Cardiomyopathy. Radiology. 2018;288:398-406. doi:10.1148/radiol.2018172613.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Crouser ED, Ruden E, Julian MW, et al. Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis. J Investig Med. 2016;64:1148-50. doi:10.1136/jim-2016-000144.</mixed-citation><mixed-citation xml:lang="en">Crouser ED, Ruden E, Julian MW, et al. Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis. J Investig Med. 2016;64:1148-50. doi:10.1136/jim-2016-000144.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology. 2005;46:1076-84. doi:10.1016/j.jacc.2005.05.073.</mixed-citation><mixed-citation xml:lang="en">Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology. 2005;46:1076-84. doi:10.1016/j.jacc.2005.05.073.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Bokhari S, Castaño A, Pozniakoff T, et al. 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circulation: Cardiovascular Imaging. 2013;6:195-201. doi:10.1161/CIRCIMAGING.112.000132.</mixed-citation><mixed-citation xml:lang="en">Bokhari S, Castaño A, Pozniakoff T, et al. 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circulation: Cardiovascular Imaging. 2013;6:195-201. doi:10.1161/CIRCIMAGING.112.000132.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Tower-Rader A, Jaber WA. Multimodality Imaging Assessment of Fabry Disease. Circulation: Cardiovascular Imaging. 2019</mixed-citation><mixed-citation xml:lang="en">Tower-Rader A, Jaber WA. Multimodality Imaging Assessment of Fabry Disease. Circulation: Cardiovascular Imaging. 2019</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
